Suppr超能文献

凝血因子V的促凝和抗凝特性在血栓形成和出血性疾病发病机制中的作用

Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.

作者信息

Dahlbäck Björn

机构信息

Department of Translational Medicine, Lund University, Malmö, Sweden.

Wallenberg Laboratory, University Hospital, Malmö, Sweden.

出版信息

Int J Lab Hematol. 2016 May;38 Suppl 1:4-11. doi: 10.1111/ijlh.12508. Epub 2016 May 9.

Abstract

Factor V (FV) serves an important role in the regulation of blood coagulation, having both pro- and anticoagulant properties. The circulating high molecular weight single-chain FV molecule undergoes a series of proteolytic cleavages during both activation of coagulation and during anticoagulant regulation of coagulation by activated protein C (APC). It is noteworthy that mutations in the factor V gene (F5) either cause thrombosis or bleeding. New insights into the importance and complexity of FV functions have been generated from elucidation of the pathogenic mechanisms of two familial mutations in the F5 gene. The first mutation was identified as a result of the discovery of APC resistance as the most common risk factor for venous thrombosis. The mutation (FV Leiden) predicts the Arg(506) Gln replacement, which impairs the normal regulation of FVa by APC, as the Arg506 site is an important APC cleavage site. In addition, elucidation of APC resistance resulted in the discovery of the anticoagulant APC cofactor activity of FV. The second FV mutation (FV(A2440G) ), identified in a family with an autosomal dominant bleeding disorder, has led to the discovery of an alternative splicing generating a previously unidentified FV isoform (FV-Short), which inhibits coagulation via an unexpected and intriguing mechanism involving the coagulation inhibitor TFPI-α. These are naturally occurring mutations in the F5 gene that have generated new knowledge on the role of FV in regulation of coagulation and the importance of genetic risk factors for thrombosis and bleeding.

摘要

凝血因子V(FV)在血液凝固调节中发挥重要作用,兼具促凝和抗凝特性。循环中的高分子量单链FV分子在凝血激活过程以及活化蛋白C(APC)对凝血的抗凝调节过程中都会经历一系列蛋白水解切割。值得注意的是,凝血因子V基因(F5)的突变要么导致血栓形成,要么导致出血。通过阐明F5基因中两个家族性突变的致病机制,人们对FV功能的重要性和复杂性有了新的认识。第一个突变是由于发现APC抵抗是静脉血栓形成最常见的危险因素而被确定的。该突变(FV莱顿)预测了精氨酸(506)被谷氨酰胺取代,这损害了APC对FVa的正常调节,因为精氨酸506位点是一个重要的APC切割位点。此外,对APC抵抗的阐明导致了FV抗凝APC辅因子活性的发现。在一个患有常染色体显性出血性疾病的家族中发现的第二个FV突变(FV(A2440G)),导致发现了一种选择性剪接,产生了一种以前未被识别的FV异构体(FV-Short),它通过一种涉及凝血抑制剂TFPI-α的意想不到且引人入胜的机制抑制凝血。这些是F5基因中的自然发生突变,它们产生了关于FV在凝血调节中的作用以及血栓形成和出血的遗传危险因素重要性的新知识。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验